Udenafil Lunch and Learn with Dr. David Goldberg

TL;DR

Dr. Goldberg discusses Udenafil's potential for Fontan patients.

Transcript

good afternoon everybody on the east coast it is now noon and we are live with dr goldberg from children's hospital of philadelphia otherwise known as chop uh and we are so excited to bring this lunch and learn to you today um we are going to be discussing the eudenophil fuel trial and give you the updates on what they learned during the trial and ... Read More

Key Insights

• The FUEL trial investigates Udenafil's effects on exercise capacity in adolescents with Fontan physiology, showing potential benefits.
• Fontan physiology is a surgical procedure that allows survival in single ventricle heart disease but is not a complete anatomical correction.
• Udenafil demonstrated improvements in sub-maximal exercise performance and was well tolerated with minimal side effects.
• The trial faced challenges in improving peak exercise capacity for those already performing at normal levels.
• Udenafil could become the first approved medication specifically for patients with Fontan physiology, pending FDA approval.
• The trial involved 30 sites globally and included meticulous safety and efficacy evaluations.
• Future studies will focus on Udenafil's long-term safety and impact on liver function in Fontan patients.
• Patient and family participation was crucial to the trial's success, highlighting the importance of advocacy and collaboration.

Questions & Answers

Q: What is the main focus of the FUEL trial?

The FUEL trial focuses on evaluating Udenafil's effects on exercise capacity in adolescents with Fontan physiology. It aims to determine if Udenafil can improve exercise performance and ventricular function, which are crucial for long-term health outcomes in these patients.

Q: What challenges did the FUEL trial face regarding peak exercise capacity?

The FUEL trial faced challenges in improving peak exercise capacity for participants already performing at normal levels. This limitation was not anticipated during the study design, but analyses are ongoing to better understand and address this issue, focusing on those who need improvement.

Q: Why is Udenafil significant for Fontan patients?

Udenafil is significant for Fontan patients because it could become the first approved medication specifically targeting their unique physiological needs. It aims to improve pulmonary blood flow and exercise capacity, potentially reducing complications and improving long-term survival rates.

Q: How does Udenafil differ from Sildenafil?

Udenafil differs from Sildenafil mainly in its dosing regimen and side effect profile. Udenafil is taken twice daily, making it more convenient than Sildenafil, which requires dosing every eight hours. Udenafil also has a favorable safety profile with fewer side effects like vision and hearing issues.

Q: What are the next steps for Udenafil after the FUEL trial?

The next steps for Udenafil include evaluating its long-term safety in the FUEL open-label extension study and assessing its impact on liver function in the FUEL Fontan-associated liver disease trial. Additionally, the NDA process with the FDA is underway to seek approval for its use in Fontan patients.

Q: What role did patient advocacy play in the FUEL trial?

Patient advocacy played a crucial role in the FUEL trial by providing support, inspiration, and participation. Advocacy groups helped emphasize the trial's importance and encouraged patient and family involvement, which was essential for the trial's success and future FDA considerations.

Q: How does Fontan physiology affect patients long-term?

Fontan physiology, though life-saving, is not a complete anatomical correction and can lead to long-term complications due to increased central venous pressure and low cardiac output. These issues can affect liver function and overall health, making effective medical therapies like Udenafil crucial.

Q: What is the significance of the NDA process for Udenafil?

The NDA process is critical for Udenafil as it seeks FDA approval to become the first medication specifically for Fontan patients. Approval would allow physicians to prescribe Udenafil, providing a scientifically backed treatment option that could improve patient outcomes and quality of life.

Summary & Key Takeaways

• Dr. David Goldberg presents the FUEL trial, which examines Udenafil's potential to improve exercise capacity in adolescents with Fontan physiology. The trial shows promising results, with Udenafil improving sub-maximal exercise performance and being well tolerated.

• Fontan physiology, a surgical solution for single ventricle heart disease, is not a complete anatomical correction. Udenafil aims to enhance pulmonary blood flow, potentially improving long-term outcomes for patients with this condition.

• The trial's success relied heavily on global collaboration and patient participation. If approved by the FDA, Udenafil would be the first medication available for Fontan patients, marking a significant advancement in treatment options.